BioSpace News Archive

The Chicago Fire Department (CFD) will be joining forces with the American Cancer Society in Illinois (ACS-IL) to launch Breast Cancer Awareness Month. CFD — who currently has the

OrthoSelect, a leading orthodontics software company and digital orthodontics lab, announces an exclusive partnership to manufacture and distribute the Owen Tripod Splint for treatment of bruxism and temporomandibular disorders.

Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A. Kelly to its Board of Directors.

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the receipt of Ethics Committee approval in the U.K. for the Company’s Cancer Appetite Recovery Study (CAReS) entitled A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announces its annual business update.

Astellas Venture Management (President: Kazunori Maruyama, Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Mission Bay Capital BioLabs (“MBC BioLabs”), a life-science incubator, today announced their second collaboration on the “Golden Ticket Competition”.

Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced the completion of a $6.5M Series A round of financing.

ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay.

Evolent Health, Inc. (NYSE: EVH) (the “Company” or “Evolent”), a health care company that delivers proven clinical and administrative solutions to payers and providers, will host a virtual Investor and Analyst Day today

Genosity Inc., and Olink Proteomics AB announced today that they have entered into a strategic services and collaboration agreement within the United States. This will allow Olink to further expand its innovative protein biomarker discovery services for the U.S. market, while enabling Genosity to add high throughput proteomics to its repertoire of available technologies. Genosity is a biotechnology company that currently of